Overexpression of the HER2/neu oncogene is observed in approximately 30% of
human breast carcinoma specimens. HER2/neu overexpression is a negative pr
ognostic factor in breast cancer patients. Cancer cells that overexpress HE
R2/neu may also be less sensitive to chemotherapy. In order to further defi
ne mechanisms by which HER2/neu overexpression drives neoplastic cell growt
h and chemoresistance, antisense oligonucleotides (ODNs) have been utilized
to selectively down-regulate HER2/neu expression in human breast cancer ce
lls. Such antisense ODNs suppress HER2/neu mRNA and protein levels in a dos
e-dependent, sequence-specific manner. Down-regulation of HER2/neu expressi
on in HER2/neu overexpressing breast cancer cells inhibits cell cycle progr
ession in G(0)/G(1) and results in apoptotic cell death. In tissue culture
studies, combined treatment of HER2/neu overexpressing breast cancer cells
with HER2/neu antisense ODNs and conventional chemotherapeutic agents resul
ts in synergistic inhibition of cancer cell growth and activation of apopto
tic cell death mechanisms. These studies have been extended to demonstrate
synergistic antitumor effects following systemic treatment with antisense O
DNs plus doxorubicin in nude mice bearing human breast carcinoma xenografts
. Collectively these findings demonstrate that HER2/neu overexpression stim
ulates anti-apoptotic cell survival mechanisms and suggest that HER2/neu an
tisense ODNs may be of use in cancer therapeutics.